EptivA Therapeutics has developed the first precision medicine approach to pain to create more effective treatments and increase clinical success.
Current R&D still relies on non-translatable preclinical models with a focus on a single node of data, the target receptor
Our innovative new approach
We have created a Personalized Analgesics® bioinformatic approach which creates 1000’s nodes of data via novel human-focused network biology linked to our proprietary Pain Landscape®
EptivA Therapeutics Ltd has a patent pending for research and methods relating to Personalized Analgesics® research
A case study: EPT-101
EPT-101 represents a novel, non-opioid analgesic for specific pain conditions identified via our technology
Using the Personalized Analgesics® research platform we have identified a previously unknown local application for EPT-101 in pain, particularly forms of neuropathic pain.
Our research shows that EPT-101 modulates mechanisms which reduce the keratin sensitization, immuno-inflammation and neuronal hyperexcitibility which drives pain in specific neuropathy conditions.
Our data has being used to create new IP to protect EPT-101 for its use in pain.